Skip to Content
  1. All products
  2. Fitness & Performance
  3. CJC-1295 With DAC
  4. Fitness & Performance
Pricelist: Default Pricelist Pricelist
Pricelist: Default Pricelist Pricelist
CJC-1295 With DAC

CJC-1295 With DAC

Lyophilized Vial · Subcutaneous Refrigerate 2–8°C · 18-month shelf life 99% Purity · USP Grade
99% Purity
PHYSICIAN USE ONLY
$ 45.00 $ 45.00

Format
💉 vial
  • Strength
Add to cart
Terms and Conditions
30-day money-back guarantee
Shipping: 2-3 Business Days
Clinical Description

GH Optimization, Anti-Aging, Body Composition, IGF-1 Elevation, Recovery Enhancement

CJC-1295 With DAC utiliza un Drug Affinity Complex para extender la vida media a 6-8 días, permitiendo dosificacion semanal y una elevación sostenida de GH. Es especialmente util en protocolos de antienvejecimiento y recomposicion corporal que requieren una elevación constante de IGF-1.

Clinical Indications
GH OptimizationAnti-AgingBody CompositionIGF-1 ElevationRecovery Enhancement
Recommended Stacking Protocols
✓
Ipamorelin
GHRH + GHRP combination for maximal GH pulse
✓
AOD-9604
Lipolysis enhancement

Mechanism of Action - Growth Hormone Peptides Pathway

Extended GHRH Agonism
DAC technology binds serum albumin extending half-life to 6–8 days for sustained GH stimulation.
Steady IGF-1 Elevation
Continuous GH stimulation maintains elevated IGF-1 without pulsatile highs/lows.
DAC Technology
Drug Affinity Complex reacts with albumin Cys-34 in vivo for extended pharmacokinetics.
Starting Dose
1 mg
Initiation phase for tolerance and baseline response.
Titration
1–2 mg
Maintenance Range
1 mg
Adjust based on objective outcomes and physician review.
Suggested Dosing Notes

Dosis inicial: 1 mg

Titulación: 1-2 mg

Rango habitual de mantenimiento: 1 mg

Vía: Una vez por semana · inyección subcutánea

Ciclo: De acción prolongada: suele ser suficiente una dosis semanal

Period Dose Phase Clinical Notes
Ongoing 1–2 mg maintenance Once weekly SQ. Monitor IGF-1 quarterly.
Preparation Protocol
  1. CJC-1295 se suministra como polvo liofilizado.
  2. CJC-1295 debe reconstituirse con agua bacteriostática antes de su uso.
  3. Elija el volumen de reconstitución según el tamaño del vial para facilitar la dosificación.
1
Verify Lyophilized Powder
Confirm the vial contains an intact white or off-white powder cake. Check lot number and expiration date.
2
Gather Sterile Supplies
Required: bacteriostatic water (BW), 1 mL insulin syringe, alcohol swabs, sharps container. Confirm all supplies are sterile and within date.
⚠️ Use only bacteriostatic water. Standard sterile water significantly reduces peptide stability.
3
Select Reconstitution Volume
Choose BW volume based on vial size and target concentration. See Reconstitution Guide tab for exact volumes per strength.
4
Reconstitute the Vial
Wipe stopper with alcohol swab. Inject BW slowly along the glass wall — never directly onto the powder. Allow liquid to run down the sides.
⚠️ Do not shake. Gently swirl or roll between palms (30–60 sec). Shaking causes irreversible peptide degradation.
5
Inspect & Store
Solution should be clear and colorless or slightly yellow. Discard if cloudy or particulate. Store reconstituted at 2–8°C, use within 28 days. Label with date.
Reconstitution & Dosing Guide
Standard 1 mL insulin syringe: 100 units = 1 mL

Total Peptide: 2 mg
BW: 2 mL
Concentration: 1 mg/mL
Dose Units to Draw Volume (mL) Approx. Supply
1 mg 100 1.00 mL 2 doses
2 mg 200 2.00 mL 1 dose
Identity
  • Name: CJC-1295 With DAC
  • CAS Number: 863288-34-0
  • Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
  • Molecular Weight: 3,647.1 Da
  • Sequence / Type: Modified GHRH + DAC linker
  • Available Strengths: 2mg, 5mg
Quality & Purity
  • Purity: ≥ 99%
  • Endotoxin: ≤ 1 EU/mg
  • Appearance: White lyophilized powder
  • Solubility: Bacteriostatic water
Storage & Handling
  • Pre-use Storage: -20°C (long-term) / 2–8°C (short)
  • Post-Reconstitution: 2–8°C · Up to 28 days
  • Shelf Life: 18 months from manufacture

Timing: Use consistent administration timing for stable protocol tracking.

Storage: Refrigerate 2–8°C · 18-month shelf life

Frequency: Frequency follows protocol phase and physician direction.

Cycle: Cycle length and cadence are clinician-defined per patient profile.

Injection Sites: Rotate approved injection sites to reduce local irritation risk.